2025-06-03-Jefferies-Kura（KURA）_ASCO25_Menin抑制剂在复发_难治性NPM1突变急性髓系白血病关键数据细节令人印象深刻_13页_5mb

报告摘要

ASCO25 Highlights: Post-ASCO25 data from the KOMET-001 pivotal trial in relapsed/refractory (r/r) NPM1m acute myeloid leukemia (AML) showed a 23% CR/CRh rate in 92 patients. Favorable safety profile with low Grade 3+ TRAEs and no Grade 4/5 events. Response persistence (DOR) at 3.7 months. Median OS in responders exceeded non-responders.
Regulatory Status: FDA accepted NDA under Priority Review; PDUFA date set for Nov 30, 2025.
Investor Event: Management confirmed Phase 3 studies for first-line (1L) use and expansion into FLT3+ AML.

Efficacy:
- 23% CR/CRh response rate; 63% MRD negativity in responders.
- 21% transfusion independence; stronger clinical benefit in MRD-negative patients.
- Consistent efficacy across subgroups (previous ven therapy, FLT3/IDH mutations).
Safety:
- Low myelosuppression, no QTc prolongation concerns (differentiated from competitor).
- Transient differentiation syndrome managed with protocol guidance.

Valuation:
- Current market cap: $643.2M; price target $28 (420% upside).
- DCF-based PT driven by NPM1m AML market opportunity ($2.7B-$3.5B peak sales).
Catalysts:
- EHA25: KOMET-001 detailed results; 2H25 initiation of KOMET-017 (1L combo trial).
- 4Q25 potential commercial launch post-approval.
Downside Risks:
- Clinical/regulatory/regulatory hurdles vs. competitors (e.g., revumenib).
- Competition in r/r NPM1m AML and ex-US sales limitations.

Market Size: ~$350–400M for r/r NPM1m AML (20% primary refractory, 50% relapsing post-CR).
Positioning: Well suited for community settings due to oral QD dosing, no cardiac monitoring, and minimal DDI concerns.
Launch: Expected 4Q25.

Recommendation: BUY with $28 PT based on 1L potential and competitive safety/tolerability.
Upside Scenario: $3.5B+ sales in AML (85-100% probability).
Downside Risk: High sensitivity to clinical trial outcomes and regulatory delays.

展开完整摘要